![](/img/cover-not-exists.png)
PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
D Heigener, HG Bischoff, C Wiesner, R AultmanVolume:
12
Year:
2009
Language:
english
DOI:
10.1016/s1098-3015(10)74292-3
File:
PDF, 92 KB
english, 2009